Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering small molecule precision medicines for serious muscle diseases. Its lead candidate, sevasemten, is an oral fast myosin inhibitor in late-stage trials for Duchenne and Becker muscular dystrophies. The company also advances EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF in Phase 1, and preclinical program EDG-003 for cardiometabolic diseases, retaining global rights to all programs.
expected 2027-02-03
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001104659-26-020112 | EDGAR | 100K words |
| 2025-03-03 | 2024-12-31 | 0001558370-25-002006 | EDGAR | 96K words |
| 2024-02-22 | 2023-12-31 | 0001558370-24-001467 | EDGAR | 98K words |
| 2023-02-23 | 2022-12-31 | 0001558370-23-001895 | EDGAR | 98K words |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001850 | EDGAR | 95K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-04 | 2026-09-30 | 0001104659-26-122653 | EDGAR | 71K words |
| 2026-08-06 | 2026-06-30 | 0001104659-26-091670 | EDGAR | 68K words |
| 2025-11-06 | 2025-09-30 | 0001104659-25-107427 | EDGAR | 68K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010655 | EDGAR | 67K words |
| 2025-05-08 | 2025-03-31 | 0001558370-25-006857 | EDGAR | 65K words |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014762 | EDGAR | 67K words |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011477 | EDGAR | 66K words |
| 2024-05-09 | 2024-03-31 | 0001544784-24-000056 | EDGAR | 64K words |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018427 | EDGAR | 67K words |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014410 | EDGAR | 66K words |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009268 | EDGAR | 64K words |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016149 | EDGAR | 67K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-04 | 0001104659-26-122654 | EDGAR | 2K words |
| 2026-08-06 | 0001104659-26-091671 | EDGAR | 2K words |
| 2026-07-13 | 0001104659-26-082902 | EDGAR | 2K words |
| 2026-02-26 | 0001104659-26-020108 | EDGAR | 2K words |
| 2025-11-20 | 0001104659-25-114660 | EDGAR | 1K words |
| 2025-11-10 | 0001104659-25-109295 | EDGAR | 1K words |
| 2025-11-06 | 0001104659-25-107419 | EDGAR | 2K words |
| 2025-08-07 | 0001104659-25-074987 | EDGAR | 3K words |
| 2025-06-26 | 0001104659-25-063028 | EDGAR | 2K words |
| 2025-05-08 | 0001104659-25-045896 | EDGAR | 3K words |
84 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001710072 |
| Ticker | EWTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.edgewisetx.com |
| Listed | 2021-03-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/EWTX (~200 tokens, structured JSON with cryptographic provenance)